Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial

NCT06623487 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06623487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06623487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Recruiting
Start date
July 19, 2024
Completion date
July 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, neoadjuvant immunotherapy, pet / ct